Congressional filings reveal new positions in Boston Scientific and Accenture, as BSX bulls argue the stock's 50% drop ignores strong core growth and a recovery in manufacturing operations.
Boston Scientific shares have drawn fresh interest from U.S. lawmakers despite a 50% year-to-date decline following a disruptive cyberattack. While the company has resumed manufacturing and distribution, investors remain divided over whether the stock's valuation reflects a permanent loss of market share or a temporary setback for a fundamentally growing business.
The decline is primarily attributed to a cyberattack that disrupted the company's manufacturing, order processing, and shipping capabilities, leading management to withdraw its financial outlook.
As of September 8, 2026, the company reported that major distribution centers are shipping at or above normal levels and manufacturing has restarted at most facilities.